Enzo Biochem, Farmingdale, NY, now offers a SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) kit for serological detection of IgG antibodies against the novel coronavirus under FDA emergency use authorization.
The new assay permits the qualitative detection of IgG antibodies to SARS-CoV-2 in human serum, and is designed to provide accurate results in a clinical laboratory setting with low- to high-throughput processing of specimens.
“Serological testing will play a critical role in identifying individuals who are transitioning to postinfection status and have developed an immune response,” says Elazar Rabbani, PhD, chief executive officers of Enzo Biochem. “While some competitor assays detect total immunoglobulin with no differentiation between immunoglobulin types, Enzo’s serological assays differentiate between these immunoglobulin types, thereby providing more information to clinicians for determining particular stages of infection.
“As with the launch of Enzo’s molecular test for the detection of active coronavirus infection, our serological assay test kit will be available for purchase by other clinical labs and is being used to perform serological testing at Enzo’s own CLIA-certified laboratory,” Rabbani adds.
For more information, visit Enzo Biochem.
